Document is current
Any future updates will be listed below
-
Authors
Ma, Huiting
Villalobos, Conrado Franco
St-Jean, Martin
Eyawo, Oghenowede
Lavergne, Miriam Ruth
Ti, Lianping
Hull, Mark W.
Yip, Benita
Wu, Lang
Hogg, Robert S.
Barrios, Rolando
Shoveller, Jean A.
Montaner, Julio S. G.
Lima, Viviane D. http://orcid.org/0000-0003-4943-091X
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA036307)
National Institute on Drug Abuse (R01DA031043)
Institute of Health Services and Policy Research (PJT-148595)
Canadian Institutes of Health Research (New Investigator Award)
Michael Smith Foundation for Health Research (Scholar Award)
British Columbia Ministry of Health
- License Information
-
More Information
Article History
Received: 9 June 2017
Accepted: 15 April 2018
First Online: 2 May 2018
Ethics approval and consent to participate
: Administrative database linkage and use was approved and performed by data stewards in each collaborating agency and facilitated by the BC Ministry of Health. The University of British Columbia Ethics Review Committee at the St. Paul’s Hospital site provided ethics approval for this study (H08–02095). The study complies with BC’s Freedom of Information and Protection of Privacy Act. As the study was conducted using anonymized administrative databases, informed consent was not obtained.
: We have the following competing interests: JSGM has received limited unrestricted funding, paid to his institution, from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, ViiV Healthcare. MH has received honoraria for speaking engagements and/or consultancy meetings from the following: Bristol Myers Squibb, Gilead, Merck, Ortho-Janssen, and ViiV. The remaining authors do not have conflicts to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
